<SEC-DOCUMENT>0001956827-24-000017.txt : 20241114
<SEC-HEADER>0001956827-24-000017.hdr.sgml : 20241114
<ACCEPTANCE-DATETIME>20241114160047
ACCESSION NUMBER:		0001956827-24-000017
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20240930
FILED AS OF DATE:		20241114
DATE AS OF CHANGE:		20241114

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Abivax S.A.
		CENTRAL INDEX KEY:			0001956827
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41842
		FILM NUMBER:		241461483

	BUSINESS ADDRESS:	
		STREET 1:		7 BD HAUSSMANN
		CITY:			PARIS
		STATE:			I0
		ZIP:			75009
		BUSINESS PHONE:		01 53 83 09 63

	MAIL ADDRESS:	
		STREET 1:		7 BD HAUSSMANN
		CITY:			PARIS
		STATE:			I0
		ZIP:			75009
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>a6-kq3keyfinancials.htm
<DESCRIPTION>6-K
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ic3c419f3dee74dc5b511a19e3cc7bd56_36"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNITED STATES</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FORM 6-K</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES EXCHANGE ACT OF 1934</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">For the month of November 2024</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Commission file number&#58; 001-41842</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:112%">Abivax SA</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(Exact name of Registrant as specified in its charter and translation of Registrant&#8217;s name into English)</font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">7-11 boulevard Haussmann</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">75009 Paris, France</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(Address of principal executive offices)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Form 20-F &#9746; Form 40-F &#9744; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On November 14, 2024, Abivax SA (the &#34;Registrant&#34;) issued a press release announcing key financial information as of September 30, 2024, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The preliminary financial data included in this Form 6-K has been prepared by, and is the responsibility of, the Registrant. PricewaterhouseCoopers Audit has not audited, reviewed, examined, compiled, nor applied agreed-upon procedures with respect to the preliminary financial data. Accordingly, PricewaterhouseCoopers Audit does not express an opinion or any other form of assurance with respect thereto.</font></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:13.643%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.157%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:125%;text-decoration:underline">Exhibit Index</font></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Exhibit 99.1</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"><a href="a6-kkeyfinancialresultsq32.htm" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%;text-decoration:none">Press release, dated November 14, 2024</a></font></div></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="ic3c419f3dee74dc5b511a19e3cc7bd56_42"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">SIGNATURES</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.983%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.944%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.773%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">Abivax SA</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(Registrant)</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Date&#58; November 14, 2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">&#47;s&#47; Marc de Garidel</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Chief Executive Officer</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a6-kkeyfinancialresultsq32.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i305eed4de7f5428c8606036410147b22_49"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div></div><div style="text-align:center"><font style="color:#614dd1;font-family:'Verdana',sans-serif;font-size:20pt;font-weight:700;line-height:112%">Abivax presents third quarter 2024 key financial information</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:112%">PARIS, France, November 14, 2024, 10&#58;00 p.m. CEST &#8211; </font><font style="color:#13284b;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Abivax SA (Euronext Paris&#58; FR0012333284 &#8211; ABVX &#47; Nasdaq &#8211; ABVX)</font><font style="color:#13284b;font-family:'Verdana',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%"> </font><font style="color:#13284b;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(&#8220;Abivax&#8221; or the &#8220;Company&#8221;), a clinical-stage biotechnology company focused on developing therapeutics that harness the body&#8217;s natural regulatory mechanisms to modulate the inflammatory response in patients with chronic inflammatory diseases, announces today its key financial information for the quarter ended September 30, 2024. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#13284b;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Abivax provided the following updates on its business and operational goals in press releases published&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#13284b;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#13284b;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:12.55pt">On July 15, 2024 press release titled &#8220;Abivax provides operational and key program update&#8221;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#13284b;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#13284b;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:12.55pt">On August 6, 2024 press release titled &#8220;Abivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment Milestone&#8221;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#13284b;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#13284b;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:12.55pt">On September 9, 2024 press release titled &#8220;Abivax presents first-half 2024 financial results&#8221;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#13284b;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#13284b;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:12.55pt">On September 25, 2024 press release titled &#8220;Abivax Provides Update on Ulcerative Colitis (UC) Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease (IBD) Mouse Model&#8221;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#13284b;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#13284b;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:12.55pt">On October 3, 2024 press releases titled &#8220;Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance&#8221; and &#8220;Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn&#8217;s Disease&#8221;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#13284b;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#13284b;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:12.55pt">On October 7, 2024 press release titled &#8220;Abivax Congratulates Victor Ambros and Gary Ruykun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation&#8221;</font></div><div><font><br></font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#614dd1;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Third Quarter 2024 Financial Highlights Preliminary Results</font></div><div><font style="color:#614dd1;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(Consolidated, unaudited results)</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Cash and Cash Equivalents&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Abivax had cash and cash equivalents of EUR 180.5 million as of September 30, 2024.  Based on the current operating plan and financial projections, the Company expects to be able to fund its operations into Q4 2025.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Principal Debt Outstanding&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Abivax had total principal debt outstanding of EUR 106.3 million as of September 30, 2024, compared to EUR 108.4 million as of June 30, 2024.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.887%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.921%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.771%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.921%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.929%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#614dd2;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#ffffff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Principal Debt Outstanding</font><font style="color:#ffffff;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">*</font></div></td><td colspan="3" style="background-color:#614dd2;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#614dd2;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#614dd2;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#614dd2;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#614dd2;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#614dd2;border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">in millions of euros</font></div></td><td colspan="3" style="background-color:#614dd2;padding:0 1pt"></td><td colspan="3" style="background-color:#614dd2;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#ffffff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">30&#47;09&#47;2024</font></div></td><td colspan="3" style="background-color:#614dd2;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#ffffff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">30&#47;06&#47;2024</font></div></td><td colspan="3" style="background-color:#614dd2;padding:0 1pt"></td><td colspan="3" style="background-color:#614dd2;border-left:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Change</font></div></td></tr><tr style="height:5pt"><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#614dd2;border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#ffffff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Debt Facility</font></div></td><td colspan="3" style="background-color:#614dd2;padding:0 1pt"></td><td colspan="3" style="background-color:#614dd2;padding:0 1pt"></td><td colspan="3" style="background-color:#614dd2;padding:0 1pt"></td><td colspan="3" style="background-color:#614dd2;padding:0 1pt"></td><td colspan="3" style="background-color:#614dd2;border-left:1pt solid #000000;border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Kreos&#47;Claret Financing</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#13284b;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">75.0</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#13284b;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">75.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#13284b;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">0.0</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Heights Convertible Notes</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#13284b;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">26.3</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#13284b;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">28.4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#13284b;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">-2.1</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">BPI Conditional Advances</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#13284b;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2.5</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#13284b;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2.5</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#13284b;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">0.0</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">State Guaranteed Loan - &#8220;PGE&#8221;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#13284b;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2.5</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#13284b;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2.5</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#13284b;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">0.0</font></td></tr><tr style="height:5pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#614dd2;border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#ffffff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Total Principal Debt Outstanding</font></td><td colspan="3" style="background-color:#614dd2;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#614dd2;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#ffffff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">106.3</font></td><td colspan="3" style="background-color:#614dd2;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#ffffff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">108.4</font></td><td colspan="3" style="background-color:#614dd2;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#614dd2;border-bottom:1pt solid #000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#ffffff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">-2.1</font></td></tr></table><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">*</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Principal debt consists of principal cash owed for each respective instrument, excluding impact of fair-value adjustments and&#47;or derivatives. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The preliminary financial data included in this press release has been prepared by, and is the responsibility of, Abivax's management. PricewaterhouseCoopers Audit has not audited, reviewed, examined, compiled, nor applied agreed-upon procedures with respect to the preliminary financial data. Accordingly, PricewaterhouseCoopers Audit does not express an opinion or any other form of assurance with respect thereto.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i305eed4de7f5428c8606036410147b22_55"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:112%">*****</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:112%">About Abivax </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body&#8217;s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Based in France and the United States, Abivax&#8217;s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis. More information on the Company is available at </font><font style="color:#614dd1;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%">www.abivax.com</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. Follow us on LinkedIn and on X, formerly Twitter, &#64;ABIVAX.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Contacts&#58;</font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Abivax Investor Relations</font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Patrick Malloy</font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%">patrick.malloy&#64;abivax.com</font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%">+1 847 987 4878</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:112%">FORWARD-LOOKING STATEMENTS</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:112%">This press release contains forward-looking statements, forecasts and estimates, including those relating to the Company&#8217;s business and financial objectives. Words such as &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;project&#8221;  and variations of such words and similar expressions are intended to identify forward-looking statements. These forward-looking statements include statements concerning or implying Abivax&#8217;s cash runway and other statements that are not historical fact. Although Abivax&#8217;s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks, contingencies and uncertainties, many of which are difficult to predict and generally beyond the control of Abivax, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. A description of these risks, contingencies and uncertainties can be found in the documents filed by the Company with the French Autorit&#233; des March&#233;s Financiers pursuant to its legal obligations including its universal registration document (Document d&#8217;Enregistrement Universel) and in its Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission on April 5, 2024 under the caption &#8220;Risk Factors.&#8221; These risks, contingencies and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug candidate, as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, and the availability of funding sufficient for the Company&#8217;s foreseeable and unforeseeable operating expenses and capital expenditure requirements. Special consideration should be given to the potential hurdles of clinical and pharmaceutical development including further assessment by the Company and regulatory agencies and IRBs&#47;ethics committees following the assessment of preclinical, pharmacokinetic, carcinogenicity, toxicity, CMC and clinical data. Furthermore, these forward-looking statements, forecasts and estimates are made only as of the date of this press release. Readers are cautioned not to place undue reliance on these forward-looking statements. Abivax disclaims any obligation to update these forward-looking statements, forecasts or estimates to reflect any subsequent changes that the Company becomes aware of, except as required by law. Information about pharmaceutical products (including products currently in development) that is included in this press release is not intended to constitute an advertisement. This press release is for information purposes only, and the information contained herein does not constitute either an offer to sell, or the solicitation of an offer to purchase or subscribe for securities of the Company in any jurisdiction. Similarly, it does not give and should not be treated as giving investment advice. It has no connection with the investment objectives, financial situation or specific needs of any recipient. It should not be regarded by recipients as a substitute for exercise of their own judgment. All opinions expressed herein are subject to change without notice. The distribution of this document may be restricted by law in certain jurisdictions. Persons into whose possession this document comes are required to inform themselves about and to observe any such restrictions.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
